Practical permeability-based hepatic clearance classification system (HepCCS) in drug discovery

Future Medicinal Chemistry

Volumn 6, Issue 18, 2014, Pages 1995-2012

  Fan, Peter W ^a   Song, Yang ^b   Berezhkovskiy, Leonid M ^a   Cheong, Jonathan ^a   Plise, Emile G ^a   Khojasteh, S Cyrus ^a  

^a GENENTECH INC   (United States)

^b ChemoCentryx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; ORGANIC CATION TRANSPORTER 1; PRAVASTATIN; DRUG; ORGANIC CATION TRANSPORTER; SLC22A2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DECISION TREE; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG PENETRATION; DRUG UPTAKE; FEMALE; HEPATIC CLEARANCE CLASSIFICATION SYSTEM; HUMAN; HUMAN CELL; KIDNEY CELL; LIVER CELL; LIVER CLEARANCE; MALE; NONHUMAN; PLASMA CLEARANCE; RAT; VOLUME OF DISTRIBUTION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; CYTOLOGY; DEFICIENCY; DOG; DRUG EFFECTS; DRUG SCREENING; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KNOCKOUT MOUSE; LIVER MICROSOME; MDCK CELL LINE; METABOLISM; MOUSE; PERMEABILITY; TANDEM MASS SPECTROMETRY;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DRUG EVALUATION, PRECLINICAL; HEPATOCYTES; MADIN DARBY CANINE KIDNEY CELLS; MICE; MICE, KNOCKOUT; MICROSOMES, LIVER; MODELS, BIOLOGICAL; ORGANIC CATION TRANSPORT PROTEINS; ORGANIC CATION TRANSPORTER 1; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; RATS; TANDEM MASS SPECTROMETRY;

EID: 84919799153     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.14.141     Document Type: Article

References (30)

1. Wu CY, Benet LZ. Predicting drug disposition via application of BCS. Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22(1), 11-23 (2005
2. Rowland M, Tozer T. Clinical Pharmacokinetics Concepts and Applications (3rd Edition). Lippincott Williams & Wilkins, PA, USA, 109-117 (1995
3. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 27(11), 1350-1359 (1999
4. Jones HM, Houston JB. Substrate depletion approach for determining in vitro metabolic clearance: Time dependencies in hepatocyte and microsomal incubations. Drug Metab. Dispos. 32(9), 973-982 (2004
5. Mcginnity DF, Soars MG, Urbanowicz RA, Riley RJ. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. 32(11), 1247-1253 (2004
6. Austin RP, Barton P, Cockroft SL, Wenlock MC, Riley RJ. The influence of nonspecific microsomal binding on apparent intrinsic clearance, and its prediction from physicochemical properties. Drug Metab. Dispos. 30(12), 1497-1503 (2002
7. Obach RS, Reed-Hagen AE. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab. Dispos. 30(7), 831-837 (2002
8. Pang KS, Weiss M, Macheras P. Advanced pharmacokinetic models based on organ clearance, circulatory, and fractal concepts. AAPS J. 9(2), E268-E283 (2007
9. Pang KS, Maeng HJ, Fan J. Interplay of transporters and enzymes in drug and metabolite processing. Mol. Pharm. 6(6), 1734-1755 (2009
10. Kusuhara H, Sugiyama Y. Pharmacokinetic modeling of the hepatobiliary transport mediated by cooperation of uptake and efflux transporters. Drug Metab. Rev. 42(3), 539-550 (2010
11. Houston JB. Transporters and cytochrome P450 interplay in defining hepatic drug clearance. In: 4th European Cyprotex Drug Discovery Workshop. London, UK, 9 June 2010
12. Umehara K, Camenisch G. Novel in vitro-in vivo extrapolation (IVIVE) method to predict hepatic organ clearance in rat. Pharm. Res. 29(2), 603-617 (2012
13. Thwaites DT, Hirst BH, Simmons NL. Passive transepithelial absorption of thyrotropin-releasing hormone (TRH) via a paracellular route in cultured intestinal and renal epithelial cell lines. Pharm. Res. 10(5), 674-681 (1993
14. Irvine JD, Takahashi L, Lockhart K et al. MDCK (Madin-Darby canine kidney) cells: a tool for membrane permeability screening. J. Pharm. Sci. 88(1), 28-33 (1999
15. Huang L, Berry L, Ganga S et al. Relationship between passive permeability, efflux, and predictability of clearance from in vitro metabolic intrinsic clearance. Drug Metab. Dispos. 38(2), 223-231 (2010
16. Soars MG, Webborn PJ, Riley RJ. Impact of hepatic uptake transporters on pharmacokinetics and drug-drug interactions: use of assays and models for decision making in the pharmaceutical industry. Mol. Pharm. 6(6), 1662-1677 (2009
17. Watanabe T, Kusuhara H, Maeda K et al. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab. Dispos. 38(2), 215-222 (2010
18. Halladay JS, Wong S, Jaffer SM, Sinhababu AK, Khojasteh-Bakht SC. Metabolic stability screen for drug discovery using cassette analysis and column switching. Drug Metab. Lett. 1(1), 67-72 (2007
19. Jacobson L, Middleton B, Holmgren J et al. An optimized automated assay for determination of metabolic stability using hepatocytes: assay validation, variance component analysis, and in vivo relevance. Assay Drug Dev. Technol. 5(3), 403-415 (2007
20. Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab. Dispos. 34(7), 1175-1181 (2006
21. Berezhkovskiy LM. The influence of hepatic transport on the distribution volumes and mean residence time of drug in the body and the accuracy of estimating these parameters by the traditional pharmacokinetic calculations. J. Pharm. Sci. 100(11), 5031-5047 (2011
22. Fagerholm U. Presentation of a modified dispersion model (MDM) for hepatic drug extraction and a new methodology for the prediction of the rate-limiting step in hepatic metabolic clearance. Xenobiotica 39(1), 57-71 (2009
23. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24(7), 1227-1251 (2007
24. Soars MG, Grime K, Sproston JL, Webborn PJ, Riley RJ. Use of hepatocytes to assess the contribution of hepatic uptake to clearance in vivo. Drug Metab. Dispos. 35(6), 859-865 (2007
25. Feng B, Mills JB, Davidson RE et al. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab. Dispos. 36(2), 268-275 (2008
26. Hallifax D, Houston JB. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab. Dispos. 35(8), 1325-1332 (2007
27. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(3), 413-420 (1995
28. Brown HS, Wilby AJ, Alder J, Houston JB. Comparative use of isolated hepatocytes and hepatic microsomes for cytochrome P450 inhibition studies: Transporter-enzyme interplay. Drug Metab. Dispos. 38(12), 2139-2146 (2010
29. Paine SW, Parker AJ, Gardiner P, Webborn PJ, Riley RJ. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab. Dispos. 36(7), 1365-1374 (2008
30. Huang L, Chen A, Roberts J et al. Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds. Xenobiotica 42(9), 830-840 (2012